Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HH-101 Monotherapy in Advanced Solid Tumors
NCT07554196Phase 1Completed
- Sponsor
- Huahui Health
- Start
- Jan 2022
- Primary completion
- Aug 2023
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of HH-101 in solid tumor (4 cohorts), sponsored by Huahui Health. Primary endpoint: Incidence of adverse events (AEs), serious adverse events (SAEs), and dose limiting toxicities (DLTs) at 24 months. Started Jan 2022; status: completed.
02
Drugs
HH-101
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07554196.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07554196.